公开(公告)号：US3718667A

公开(公告)日：1973-02-27

申请号：US3718667D

申请日：1971-04-15

Applicant: AMERICAN HOME PROD

Inventor： STRIKE D ,  SMITH H

IPC: C07C17/16 ,  C07C29/42 ,  C07C45/40 ,  C07C47/263 ,  C07C49/185 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07D303/32 ,  C07D303/38 ,  C07D303/40 ,  C07D309/12 ,  C07D7/04 ,  C07C59/32

CPC classification number: C07D303/38 ,  C07C29/42 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07C405/0025 ,  C07D303/32 ,  C07D303/40 ,  C07D309/12 ,  C07C33/042

Abstract: 4,5-DISUBSTITUTED-3-HYDROXYCYCLOPENTANONES (I) ARE PREPARED BY HYDROGENOLYZING THE CORRESPONDING 4,5-DISUBSTITUTED-2,3-EPOXYCYCLOPENTANONE (IV) WHICH IN TURN IS PROVIDED BY REACTING THE CORRESPONDING 4,5-DISUBSTITUTED2-CYCLOPENTEN-1-ONE (111) WITH ALKINE HYDROGEN PEROXIDE. COMPOUNDS (111) ARE PREPARED BY CYCLIZING THE CORRESPONDING 2,3-DISUBSTITUTED LEVULINALDEHYDE (11) WITH A BASE. THE PRODUCTS OF THE PROCESS ARE BIOLOGICALLY ACTIVE, ESPECIALLY COMPOUND (1) SUBSTITUTED IN THE 4-POSITION WITH 3'', -HYDROXYOCTYL AND IN THE 5-POSITION WITH 6'' -CARBOXYHEXYL. THIS COMPOUND HAS PROSTAGLANDIN-LIKE ACTIVITY, ACTIVITY BLOOD PRESSURE LOWERING AND BRONCHODILATOR E1ESPEACTIVITY, AND IS A TOTALLY-SYNTHETIC DIHYDROPROSTAGLANDIN E1 (DIHYDRO PGE1). THE PROCESSES OF THE INVENTION MAY ALSO BE USED TO OBTAIN COMPOUNDS WITH PROSTAGLANDINLIKE ACTIVITY FROM APPROPRIATELY SUBSTITUTED NATURALLY OCCURRING CYCLOPENTANONES, E.G. THOSE ISOLATED FROM THE CARIBBEAN GORGONIAN, PLEXAURA HOMOMALLA.

公开(公告)号：US2891988A

公开(公告)日：1959-06-23

申请号：US67905757

申请日：1957-08-19

Applicant: AMERICAN CYANAMID CO

Inventor： BROCKMAN JR JOHN A ,  FRANK FABIO PAUL

IPC: C07C59/225

CPC classification number: C07C59/225 ,  Y10S435/942

公开(公告)号：US20210078941A1

公开(公告)日：2021-03-18

申请号：US16644205

申请日：2018-08-07

Applicant: Jiangsu Ruike Medical Science And Technology Co., Ltd.

Inventor： Jieping Li ,  Zhaobo Gao ,  Bing Chai ,  Hui Zheng ,  Shengmin Liu ,  Aqing Liu ,  Bibao Guo ,  Juncheng Zheng ,  Changfa Wang ,  Weiwei Lu

IPC: C07C253/30 ,  C07C51/38 ,  C07C69/757 ,  C07C67/343 ,  C07C253/14 ,  C07C255/41 ,  C07C51/08 ,  C07C59/225 ,  C07C49/467 ,  C07C45/65

Abstract: The invention belongs to the pharmaceutical manufacturing field, which relates to a novel process for the preparation of substituted phenylacetic acids derivatives, especially relates to the preparation of 2-(4-(2-oxocyclopentyl)phenyl)propanoic acid. The process for the preparation of the precursor form of loxoprofen which use 1,4-di-halobenzyl compounds or disubstituted benzyl compounds as starting material, is through the substitution reaction of cyclopentanone groups or its precursor compounds. Wherein X is halogen, L1 is a suitable leaving group selected from halogen, OH, OMs, OTs, OTf and the like; L2 is a suitable leaving group selected from halogen, CN, OH, —CH2OH, —CHO, CH3NO2, ester group, —NR4R5, OTf, OTs, OMs, —C═CR6, —C≡CR7 and the like, wherein R4, R5, R6, R7 are short chain alkyl groups; Z is cyclopentanone group and its precursor form selected from and the like; R3 is short chain alkyl groups. L3 is a suitable leaving group selected from halogen, OH, OMs, OTs, OTf and the like, or organometallic groups. The invention also include the detailed procedure to convert the precursor compounds of cyclopentanone group to cyclopentanone, followed by the transformation of the precursor compounds of loxoprofen to loxoprofen.

公开(公告)号：US20150005385A1

公开(公告)日：2015-01-01

申请号：US14486805

申请日：2014-09-15

Applicant: MediciNova, Inc.

Inventor： Kazuko MATSUDA

IPC: C07C59/225

CPC classification number: A61K31/192 ,  C07C59/225

Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

Abstract translation: 式（I）的化合物或其代谢物，或式（I）化合物或其代谢物的酯或其各自的药学上可接受的盐，其中m，n，X1和X2如本文所定义 可用于治疗非酒精性脂肪性肝病（NAFLD）或非酒精性脂肪性肝炎（NASH）。

公开(公告)号：US08759574B2

公开(公告)日：2014-06-24

申请号：US13322319

申请日：2010-05-27

Applicant: Hendrikus Wilhelmus Bakkenes ,  Roberto Aloysius Gerardus Maria Bergevoet ,  Johannes Albertus Maria Meijer ,  Maria Steensma

Inventor： Hendrikus Wilhelmus Bakkenes ,  Roberto Aloysius Gerardus Maria Bergevoet ,  Johannes Albertus Maria Meijer ,  Maria Steensma

IPC: C07C59/225

CPC classification number: C07C51/412 ,  C01D3/26 ,  C07B2200/13 ,  C07C51/487 ,  C07C59/255

Abstract: The present invention relates to a process for the preparation of a composition comprising tartaric acid wherein between 55 and 90% by weight of the tartaric acid is meso-tartaric acid, comprising the steps of (i) preparing an aqueous mixture comprising between 35 and 65% by weight of a di-alkali metal salt of L-tartaric acid, a di-alkali metal salt of D-tartaric acid, a mixture of di-alkali metal salts of L-tartaric acid, D-tartaric acid, and optionally meso-tartaric acid, and between 2 and 15% by weight of an alkali metal or alkaline metal hydroxide, and (ii) stirring and heating the aqueous mixture to a temperature of between 100° C. and its boiling point until between 55 and 90% by weight of tartaric acid has been converted to meso-tartaric acid.

Abstract translation: 本发明涉及一种制备包含酒石酸的组合物的方法，其中所述酒石酸的重量百分比为55-90％是内消旋酒石酸，包括以下步骤：（i）制备含有35至65 重量百分比的L-酒石酸的二碱金属盐，D-酒石酸的二碱金属盐，L-酒石酸的二碱金属盐，D-酒石酸和任选的内消旋 - 酒石酸和2至15重量％的碱金属或碱金属氢氧化物，和（ii）将含水混合物搅拌并加热至100℃至其沸点至55至90％之间的温度， 的酒石酸已经转化为内消旋酒石酸。

公开(公告)号：US3932467A

公开(公告)日：1976-01-13

申请号：US392317

申请日：1973-08-28

Applicant: Masateru Miyano

Inventor： Masateru Miyano

IPC: C07C59/225 ,  C07C59/90 ,  C07C59/92 ,  C07C405/00 ,  C07D309/12 ,  C07F9/54 ,  C07F7/18 ,  C07D309/06

CPC classification number: C07D309/12 ,  C07C405/00 ,  C07C59/225 ,  C07C59/90 ,  C07C59/92 ,  C07F9/5407

Abstract: 2-Formyl-3-protected hydroxy-5-oxocyclopent-1-eneheptanoic acid and its esters are stereoselectively reduced to the corresponding 2.beta.-formyl-3.alpha.-protected hydroxy-5-oxocyclopentane-1.alpha.-heptanoic acid and esters with chromous sulfate. The compounds so produced are useful as intermediates to PGE.sub.1 and its esters, which compounds exhibit hypotensive and smooth muscle-stimulating properties.

Abstract translation: 将2-甲酰基-3-保护的羟基-5-氧代环戊-1-烯庚酸及其酯立体选择性还原成相应的2β-甲酰基-3α-保护的羟基-5-氧代环戊烷-1α-庚酸和具有色素的酯 硫酸盐。 如此制备的化合物可用作PGE1及其酯的中间体，该化合物表现出降血压和平滑肌刺激性质。

公开(公告)号：US3810936A

公开(公告)日：1974-05-14

申请号：US18785371

申请日：1971-10-08

Applicant: SEARLE & CO

Inventor： MIYANO M

IPC: C07C59/225 ,  C07C59/90 ,  C07C59/92 ,  C07C405/00 ,  C07F9/54 ,  C07C61/36

CPC classification number: C07C405/00 ,  C07C59/225 ,  C07C59/90 ,  C07C59/92 ,  C07F9/5407

Abstract: THE CONDENSATION OF DIMETHYL 3-OXOUNDECANE-1,11-DIOATE WITH STYRYLGLYOXAL AFFORDS 14-PHENYL-9,12-DIOXO-11HYDROXYTETRADEC-13-ENOIC ACID, WHICH IS CYCLIZED TO AFFORD 3-HYDROXY-5-OXO-2-STYRYLCYLOPENT - 1 - ENEHEPTANOIC ACID. HYDROXYLATION OF THE STYRYL DOUBLE BOND AFFORDS THE CORRESPONDING 2-STYRYL-3-HYDROXY COMPOUNDS RE RESOLVED AND IS CLEAVED TO AFFORD THE INSTANT 2-FORMYL COMPOUNDS. THE RACEMIC 2-STYTYL-3-HYDROXY COMPOUNDS ARE RESOLVED AND SUBSEQUENTLY HYDROXYLATED AND CLEAVED TO FORM THE OPTICALLY ACTIVE 2-FORMYL DERIVATIVES. THE INSTANT COMPOUNDS ARE USEFUL AS ANTI-MICROBIAL AGENTS AND ALSO AS INTERMEDIATES TO PROSTANOIC ACID DERIVATIVES AND THEIR OPTICALLY ACTIVE ISOMERS WHICH EXHIBIT ANTI-MICROBIAL, PEPSIN-INHIBITORY, HYPOTENSIVE AND SMOOTH MUSCLE-CONTRACTING PROPERTIES.

公开(公告)号：US20250042856A1

公开(公告)日：2025-02-06

申请号：US18717134

申请日：2022-12-09

Applicant: ATROGI AB

Inventor： Benjamin Pelcman

IPC: C07D213/61 ,  A61K31/44 ,  A61K45/06 ,  A61P3/10 ,  C07C59/225

Abstract: The present invention discloses a crystalline form of the (R)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)ethanol (formula (I)) hemi-(2R,3R)-tartrate salt characterised by a melting point of 211° C. and the XRPD pattern of FIG. 1. The present invention also relates to said hemi-tartrate salt for use in the treatment of hyperglycaemia and type 2 diabetes through activation of the beta2-adrenergic receptor. Importantly, such salts are thought to have a beneficial side-effect profile as they do not exert their effect through significant cAMP release.

公开(公告)号：US3749741A

公开(公告)日：1973-07-31

申请号：US3749741D

申请日：1971-04-15

Applicant: AMERICAN HOME PROD

Inventor： STRIKE D ,  SMITH H

IPC: C07C17/16 ,  C07C29/42 ,  C07C45/40 ,  C07C45/51 ,  C07C49/185 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07D303/32 ,  C07D303/38 ,  C07D303/40 ,  C07D309/12 ,  C07D7/04

CPC classification number: C07D303/38 ,  C07C29/42 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07C405/0025 ,  C07D303/32 ,  C07D303/40 ,  C07D309/12 ,  C12C11/02 ,  C07C33/042

Abstract: 4,5-DISUBSTITUTED - 3 - HYDROXYCYCLOPENTANONES (I) ARE PREPARED BY HYDROGENOLYZING THE CORRESPONDING 4,5-DISUBSTITUTED-2,3-EPOXYCYCLOPENTANONE (IV) WHICH IN TURN IS PROVIDED BY REACTING THE CORRESPONDING 4,5 - DISUBSTITUTED-2-CYCLOPENTEN-1-ONE (III) WITH ALKALINE HYDROGEN PEROXIDE. COMPOUNDS (III) ARE PREPARED BY CYCLIZING THE CORRESPONDING 2,3-DISUBSTITUTED LEVULINALDEHYDE (II) WITH A BASE. THE PRODUCTS OF THE PROCESS ARE BIOLOGICALLY ACTIVE, ESPEICALLY COMPOUND (I) SUBSTITUTED IN THE 4-POSITION WITH 3'':HYDROXYOCTYL AND IN THE 5-POSITION WITH 6''CARBOXYHEXYL. THIS COMPOUND HAS PROSTAGLANDIN-LIKE ACTIVITY, ESPECIALLY BLOOD PRESSURE LOWERING AND BROCHODILATOR ACTIVITY, AND IS A TOTALLY-SYNTHETIC DIHYDROPROSTAGLANDIN E1(DIHYDRO PGE1). THE PROCESSES OF THE INVENTION MAY ALSO BE USED TO OBTAIN COMPOUNDS WITH PROSTAGLANDIN-LIKE ACTIVITY FROM APPROPRIATELY SUBSTITUTED NATURALLY OCCURRING CYCLOPENTANONES, E.G. THOSE ISOLATED FROM THE CARIBBEAN GORGONIAN, PLEXAURA HOMOMALLA.

公开(公告)号：US3736336A

公开(公告)日：1973-05-29

申请号：US3736336D

申请日：1971-04-15

Applicant: AMERICAN HOME PROD

Inventor： STRIKE D ,  SMITH H

IPC: C07C17/16 ,  C07C29/42 ,  C07C45/40 ,  C07C45/51 ,  C07C49/185 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07D303/32 ,  C07D303/38 ,  C07D303/40 ,  C07D309/12 ,  C07D1/20 ,  C07D1/22

CPC classification number: C07D303/38 ,  C07C29/42 ,  C07C59/215 ,  C07C59/225 ,  C07C59/90 ,  C07C405/00 ,  C07C405/0025 ,  C07D303/32 ,  C07D303/40 ,  C07D309/12 ,  C07C33/042

Abstract: 4,5-DISUBSTITUTED-3-HYDROXYCYCLOPENTANONES (I) ARE PREPARED BY HYDROGENOLYZING THE CORRESPONDING 4,5-DISUBSTITUTED-2,3-EPOXYCYCLOPENTANONE (IV) WHICH IN TURN IS PROVIDED BY REACTING THE CORRESPONDING 4,5-DISUBSTITUTED2-CYCLOPENTEN-1-ONE (III) WITH ALKALINE HYDROGEN PEROXIDE. COMPOUNDS III ARE PREPARED BY CYCLIZING THE CORRESPONDING 2,3-DISUBSTITUTED LEVULINALDEHYDE (II) WITH A BASE. THE PRODUCTS OF THE PROCESS ARE BIOLOGICALLY ACTIVE, ESPECIALLY COMPOUND I SUBSTITUTED IN THE 4-POSITION WITH 3''-HYDROXYOCTYL AND IN THE 5-POSITION WITH 6''-CARBOXYHEXYL. THIS COMPOUND HAS PROSTAGLANDIN-LIKE ACTIVITY, ESPECIALLY BLOOD PRESSURE LOWERING AND BRONCHODILATOR ACTIVITY, AND IS A TOTALLY-SYNTHETIC DIHYDROPROSTAGLANDIN E1 (DIHYDRO PGE1). THE PROCESS OF THE INVENTION MAY ALSO BE USED TO OBTAIN COMPOUNDS WITH PROSTAGLANDIN-LIKE ACTIVITY FROM APPROPRIATELY SUBSTITUTED NATURALLY OCCURRING CYCLOPENTANONES, E.G. THOSE ISOLATED FROM THE CARIBBEAN GORGONIAN, PLEXAURA HOMOMALLA.